Time to Treat and the “Golden Hour”: Why They Matter and How Clinical Pathways Can Help” was selected as one of top 5 publications in the Journal of Clinical Pathways in 2024. The announcement was made at the Clinical Pathways Congress + Cancer Business Exchange in Boston, MA, Sept 6, 2024. The article discusses XpediteMD’s novel use of cancer clinical pathways to eliminate cancer treatment delays while facilitating high quality, evidenced based cancer care. Download PDF or read the article here
“Reducing Delays of Breast Cancer Care Using an Innovative Digital Health Platform” has been accepted for publication published in the American Journal of Accountable Care. The article discusses how XpediteMD dramatically reduced breast cancer treatment delays in a major health system. Download PDF or read the full article in The American Journal of Accountable Care
“Time to Treat and the “Golden Hour”: Why They Matter and How Clinical Pathways Can Help” has been accepted for publication in the Journal of Clinical Pathways. The article discusses how XpediteMD’s proprietary clinical pathways eliminate life-threatening cancer treatment delays. The article is due for publication June 2024.
XpediteMD was a finalist in the CancerX Moonshot Accelerator Contest.
XpediteMD, Inc. has advanced to the second round of the CancerX Accelerator/Mass Challenge competition. CancerX is a public-private partnership announced by The White House as a national accelerator to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.
CMS issues new rule requiring electronic prior authorization and faster prior authorization decisions for Medicare Advantage members and others. Read more here
XpediteMD submitted invited manuscript for publication in the Journal Of Clinical Pathways, “Time To Treatment and the Golden Hour: How Clinical Pathways Can Help".
XpediteMD joins the CancerX Moonshot accelerator competition, a White House initiative public-private partnership to boost innovation in the fight against cancer.
XpediteMD submitted manuscript to American Journal of Accountable Care summarizing the XpediteMD experience at Intermountain Healthcare Nevada showing a 77% reduction in breast cancer time to treatment and an 80% reduction in administrative overhead.
SilverSummit Healthplan (Centene Nevada) sends out a press release lauding how XpediteMD is helping its breast cancer patients obtain breast cancer care much faster.
Dennis R. Holmes presented invited plenary lecture at Clinical Pathways Congress + Cancer Care Business Exchange, “Time to Treat: Why It Mattes and How Pathways Can Help.”
XpediteMD covered in news story in Journal of Clinical Pathways about XpediteMD’s innovative solution to the time to treatment problem.
XpediteMD exhibited at the upcoming annual meeting of Clinical Pathways Congress + Cancer Care Business Exchange and presented demo of XpediteMD in Vendor Forum.
XpediteMD launches its upgraded, scalable, multi-tenet, interoperable platform.
XpediteMD presented results of quality improvement initiative at the National Medical Associations’ 24th annual meeting: “Golden Hour” Redefined: The relationship between timely care and cancer survival.
XpediteMD Co-Founder and CEO, Dennis R. Holmes, MD, FACS, selected as the 2023 Health Policy Scholar for the American College of Surgeons and American Society of Breast Surgeons. The XpediteMD innovation was instrumental in Dr. Holmes’ selection as the 2023 Health Policy Scholar.
The American Medical Association launches an advocacy initiative to fix prior authorization which “hurts patients, physicians, and employers.” See how prior authorization affects you. The XpediteMD SaaS platform fixes prior authorization-related delays for cancer patients by establishing point of care prior authorizations, a new industry standard.
XpediteMD signs Technology-Enabled Service contract with major health plan for use of the breast cancer module.
XpediteMD signs Technology-Enabled Service contract with major national health plan for use of the breast cancer module.
XpediteMD presented results of quality improvement initiative at the 46th annual meeting of the San Antonio Breast Cancer Symposium reduced time to treatment by greater than 50%.
XpediteMD completes first of its kind IRB-approved quality health initiative at Intermountain Health Care Nevada which achieved a 77% reduction in time to treatment in only 12 months among Medicare Advantage breast cancer patients.
The Commission on Cancer (CoC) National Cancer Database announces a new breast quality measure that establishes “time to therapeutic breast surgery <60 days” as a surveillance measure for 1,500+ CoC-accredited sites—exactly what the XpediteMD is designed to address.
The American Society of Breast Surgeons announces a new national quality measure for timeliness of care for breast cancer, recommending that all newly diagnosed breast cancer patients initiate treatment for breast cancer within 60 days of the date of diagnosis—a challenge easily met by the XpediteMD.
The California Department of Managed Health Care and Department of Health Care Services fines L.A. Care, the nation’s largest publicly operated health plan, $55 million dollars in Enforcement Action for “operational failures” that contributed to delay of cancer care that resulted in “harm to members”—exactly the problem that the XpediteMD SaaS platform is designed to prevent.
